SCB-2019

SCB-2019 Uses, Dosage, Side Effects, Food Interaction and all others data.

SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture.

The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

Trade Name SCB-2019
Generic SCB-2019
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
SCB-2019
SCB-2019

Innovators Monograph

You find simplified version here SCB-2019


*** Taking medicines without doctor's advice can cause long-term problems.
Share